Survey Administration for Hematologic Neoplasms

More than half a million people in the United States are diagnosed with non-Hodgkin's lymphoma, and over 20,000 people are diagnosed with [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) each year. About half of hematologic neoplasms are lymphomas and about half of lymphomas are leukemias. More than half of leukemias are acute myelogenous leukemias. Other common forms of hematologic neoplasms include multiple myeloma, myeloproliferative disorders, and hairy cell leukemias and lymphomas. People with hematologic neoplasms comprise 10.5% of all Americans.

While hematologic malignancies do not always remit from chemotherapy, they are often curable or amenable to remission. It is possible for these tumors to be cured, especially if the disease is detected early on.

For myeloma, thrombocyte or erythroid precursors, and myelodysplastic syndromas, therapies include chemotherapy with anthracyclines, mitoxantrone, and platinum, followed by autologous hematopoietic stem cell transplantation. For acute leukemia, therapy often involves administration of high-dose all-trans retinoic acid, bleomycin or cytarabine alone or in combination with other drugs.

Hematologic neoplasms are a very common group of cancer types, but the most common signs are the symptoms of metastatic spread and thrombocythemia. The presence of these signs indicates the need for further investigation with other diagnostic tests such as radiographic investigations and careful blood tests (full blood count and liver tests). The presence of anemia, thrombocytosis and/or erythroplasia of chronic disease suggests the need for further investigation on a molecular level.(H).

Not all of the hematopoietic neoplasms arise from an identifiable environmental cause. The cause may be in hematopoietic cells themselves, or in the environment, which is the site where the tumors are located. The cause does not have to be clearly identifiable. Although the majority of hematopoietic neoplasms are related to the exposure to radiation and carcinogen, some tumors seem to be unrelated.

Hematologic neoplasms are cancers of the blood, bone marrow or lymph nodes. A hematologic cancer is an cancer that starts in the blood, bone marrow, or lymph nodes. Hematological neoplasms were among the 3 most common childhood cancers in the United States in 2011 as reported by the Central Cancer Registry of the Children's Oncology Group. Hematologic neoplasms accounted for about 2.9% of the cases (1,566 events of which 89 were acute leukemias, 439 lymphomas, and 238 myeloproliferative neoplasms).

Patients with a diagnosis of hematologic disease in the Netherlands can expect an overall five-year survival rate of 62% to 65%. Younger patients tend to have a better survival rate. The current results for Dutch patients with a diagnosis of multiple myeloma or non-Hodgkin's lymphoma compares favorably with results from the United States and Norway. Survival rates for patients with a diagnosis of other hematologic neoplasms are not significantly different from those expected for people in France or the United Kingdom.

Hematologic neoplasms are highly variable and have varying frequencies of hereditary origin. In some cases, a family history of a hematologic cancer underscores the possibility that a genetic factor is involved. Results from a recent paper warrant a further study of hematopoietic neoplasms based on their occurrence in certain families.

The most recent meta-analyses that investigated potential clinical benefits of immunotherapy used in advanced hematological cancers were conducted using the old definition of clinical benefit. [More work is needed to define the new definition of clinical benefit for immunotherapy. These studies should be used to implement future trials in immunotherapy for hematologic neoplasms. (JAK) The authors reviewed the existing literature up to 2016.

Surveys administered by a trained nurse or clinic visitor have no additional value for patients with hematologic neoplasms, and, where possible, patients should be surveyed by a nurse or clinic visitor instead of by mail.

Results suggest that survey administrators do have the ability to successfully treat patients with [hematological neoplasms(such as chronic lymphocytic leukemia and lymphoma) and other solid tumors(such as lung, stomach, head and neck, bladder, breast)(https://www.onc.umich.edu/research/surveys/survey_management/survey_management/surveys_administered_online.aspx). The survey administration process that is best suited for those patients will help make the survey process more efficient.